Advertisement
Advertisement
U.S. Markets open in 1 hr 14 mins
Advertisement
Advertisement
Advertisement
Advertisement

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.7800+0.0800 (+2.16%)
At close: 04:00PM EDT
3.8000 +0.02 (+0.53%)
Pre-Market: 08:08AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7000
Open3.8000
Bid3.7800 x 800
Ask4.4500 x 800
Day's Range3.5200 - 3.8250
52 Week Range0.4600 - 4.6830
Volume303,075
Avg. Volume1,480,037
Market Cap97.7M
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)-1.7560
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • PR Newswire

    Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended June 30, 2022, as well as provided business updates.

  • PR Newswire

    Trevi Therapeutics to Present at Upcoming August Conferences

    Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences:

  • PR Newswire

    Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30

Advertisement
Advertisement